- Voyager Therapeutics Inc VYGR announced preclinical data from a new vectorized anti-HER2 antibody program.
- Data showed that IV dosing of a proprietary AAV vector identified by the TRACER screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth in animal models of brain metastases.
- Peripheral administration of TRACER AAV vector resulted in the production of efficacious levels of HER2-directed antibodies for extended periods.
- Related: Voyager Therapeutics Stock Soars On License Option Pact With Pfizer.
- Price Action: VYGR shares are up 3.16% at $3.26 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
